Navigation Links
Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc.
Date:5/5/2008

WOODCLIFF LAKE, N.J., May 5 /PRNewswire/ -- Eisai Corporation of North America today announces the immediate appointment of Cynthia Schwalm as President of Eisai Inc. In her new role, Ms. Schwalm will have full operating responsibility for leading Eisai Inc., the U.S. commercial operation of Eisai Co., Ltd.

Ms. Schwalm brings to Eisai Inc. a strong track record of building high-performing organizations that drive global growth and nearly 25 years of senior healthcare experience in the fields of pharmaceuticals, biotechnology and medical devices. She will report to Lonnel Coats, President & COO, Eisai Corporation of North America. Previously, Mr. Coats held dual responsibilities, also serving as President & COO of Eisai Inc.

"Ms. Schwalm is an exciting addition to our company. She will be instrumental in driving Eisai's integration of MGI PHARMA and strengthening our presence in the U.S. as a top-20 pharmaceutical company," said Mr. Coats. "Ms. Schwalm has an extensive background in oncology, neurology, critical care and gastroenterology, areas of therapeutic focus for Eisai. She will be invaluable to our future growth, as we continue to advance our human health care (hhc) mission to satisfy unmet medical needs and increase benefits to patients and their families."

Ms. Schwalm joins Eisai from Amgen, Inc., where over the course of her five-year tenure she rose to Vice President and General Manager of the U.S. Oncology Business Unit, a group with annual revenues exceeding $5 billion. In this role she led the 500-person business unit, oversaw all oncology strategy and served as a member of Amgen's Senior Management Team responsible for talent development in medical affairs, drug development, regulatory, and health economic functions.

Prior to Amgen, Inc., Ms. Schwalm grew her pharmaceutical career over an 18-year period within Johnson & Johnson (J&J), holding positions of increasing responsibility at various J&J companies. During this
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
2. Eisai/Pfizers Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimers Disease
3. Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
4. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
5. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
6. BioElectronics Corporation Receives Major Orders From Italian Distributor
7. Oxford Finance Corporation and Comerica Bank Provide $15 Million Loan Facility to VisualSonics Inc.
8. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
9. Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
10. Dialysis Corporation of America Announces First Quarter 2008 Earnings Release Date
11. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... researchers from the University of Leicester has furthered ... the potential to create new materials using nanosized ... published in the prestigious academic journal Physical ... to examine in rich detail the structure and ... an acetylene molecule and a single helium atom. ...
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 WABC Radio ... Your Pet with Lorry Young will be hosting California-based ... talk about stem cell therapy in pets. Dr. Harman ... benefits of stem cell therapy for pets suffering from osteoarthritis ... the Regenerative Veterinary Medicine industry forward. , Young has invited ...
(Date:7/25/2014)... 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... the development and commercialization of a once-daily, oral therapy ... today announced financial results for the period ended June ... , Reported cash and cash equivalents totaling $37.4 ... December 31, 2013.  , Reported a net loss ...
(Date:7/25/2014)... July 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... June 30, 2014, after market close on Thursday, August 14, ... to the market opening on Friday, August 15, 2014, at ... China Standard Time) to review the Company,s financial results and ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2
... data from Phase 3 European clinical ... pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), ... prevalent serotypes associated with pneumococcal disease (PD), the leading cause ... , , The Phase 3 data presented at ...
... Syngenta today announced that it has ... antitoxin crop protection technology to the company,s portfolio. Circle ... reducing aflatoxin, a toxin that can develop in crops such ... , , "The acquisition of this technology adds ...
... ... Stage Solutions, Inc. has expanded its financial services offerings to further meet ... launched three new services: First, CFO on Demand - NSS partners with ... Strategic Finance - the Next Stage Solutions team equips its clients with ...
Cached Biology Technology:New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 2New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 4New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 5New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 6Syngenta Acquires Innovative Bio-Control Technology to Improve Usable Crop Yields 2Syngenta Acquires Innovative Bio-Control Technology to Improve Usable Crop Yields 3Next Stage Solutions Announces Three New Financial Services For Emerging Business 2Next Stage Solutions Announces Three New Financial Services For Emerging Business 3
(Date:7/25/2014)... for Medical Research have identified the functions of ... to triggering the mating process in mice. , They ... detect pheromones that indicate when a female is present. ... the female mouse is ovulating and ready to mate. ... Stowers, researchers believe mice developed this system through evolution ...
(Date:7/25/2014)... have detected an unknown interaction between microorganisms and salt. ... a droplet of salt water and is left to ... biomineralogical biosaline 3D morphologically complex formations, where they hibernate. ... The discovery was made by chance with a home ... Astrobiology journal and may help to find signs ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
Breaking Biology News(10 mins):It takes two to court 2It takes two to court 3Bacteria manipulate salt to build shelters to hibernate 2NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2
... tissues and organs. Because these cells are able to grow ... they hold the key to groundbreaking new therapies. To help ... found a new way to culture cells in 3D a ... body grow and divide in a 3D environment, especially when ...
... of people suffer from Parkinson,s disease, a disorder of ... time. As the world,s population ages, it,s estimated that ... sharply. Yet despite several effective therapies that treat Parkinson,s ... it,s not known what exactly causes the disease, evidence ...
... now, it was presumed that the last glacial period ... return of milder weather began and melted away the ... now disproved by research headed by Professor Eske Willerslev ... Laura Parducci from the University of Uppsala, Sweden, and ...
Cached Biology News:Parkinson's disease stopped in animal model 2Parkinson's disease stopped in animal model 3Sturdy Scandinavian conifers survived Ice Age 2Sturdy Scandinavian conifers survived Ice Age 3
The PxE Thermal Cycler (PxE) is a licensed 96 well PCR machine, developed to provide all fundamental features for value for money thermal cycling....
PxE thermal Cycler. 0.5ml block holds 48 0.5 ml tubes or 96 0.3 ml tubes. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User frien...
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
A Highly Purified, Cost-Effective Taq DNA Polymerase...
Biology Products: